Alzheimer’s And Surrogate Endpoints: FDA’s On A Case-By-Case Basis Per New Guidance

After Aduhelm and Leqembi rendered the 2018 guidance moot, FDA formally acknowledges the possibility of using surrogate endpoints for accelerated approval in Alzheimer’s in updated draft but says acceptability of the any endpoint will depend on details of specific therapeutic program.